Macau University of Science and Technology

Southern Medical University

Other

Zhi-Hong Jiang

Jing-Rong Wang

Li-Ping Bai

Guo-Yuan Zhu

Liang Liu

Jin-Xiang Chen

Bao-Ping Xie

Bin Sun

Cheng-Yu Chen

Hao Huang

Jia-Ning Mi

Qiong Meng

Tiantian Tong

Xiaobo Zhou

Weina Gao

Zifeng Yang

Nanshan Zhong

Leefong Yau

Jingrong Wang

Xiao-Jun Yao

Elaine Lai-Han Leung

Shuwen Liu

Zhen Liang

Ye-Mei Liang

Ji Yang

Yuwei Han

Jinxiang Chen

Jing Fu

Junping Kou

Jianxin Pang

Hai-Qing Zhao

Tian-Tian Tong

Beixian Zhou

Tong-Meng Yan

Zhiyuan Zheng

Kua Hu

Xin Liu

Yingqiong Xu

Yuen Kwan Betty Law

Lee-Fong Yau

Kam Wai Vincent Wong

Kai-Yue Cao

Qi-Tong Feng

Wei-Na Gao

Qitong Feng

Gui-Hua Qiu

Pei-Pei Hu

This invention discloses a medicinal composition includes a non-coding RNA molecule and an antibody targeting a tumor antigen for preventing and/or treating cancer. This invention uses the synergistic combination of a non-coding RNA molecule or its functional variant or homologue, and an antibody targeting a tumor antigen to prevent and/or treat cancer, thereby providing a novel and effective method in preventing and/or treating various cancers.

Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen

A compound including a structure of Formula (I) and a preparation method thereof, wherein Ris &#x2014;OH, &#x2014;CHOH, or &#x2014;OCOCH; R, R, and Rare independently &#x2014;H, &#x2014;CHor &#x2014;F, and at least one of R, R, and Ris &#x2014;F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

Compounds and methods for treating influenza

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from, in particular from wild-type, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from, in particular from wild-type. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject. Still further in accordance with the present invention is a composition, in particular a pharmaceutical composition comprising at least one sphingolipid portion.

Method of isolating sphingolipids from cordyceps and their use

A method of treating a subject suffering from cancer includes administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule is isolated or derived from a plant of the genus. A method of inhibiting growth or proliferation of cancer cells includes contacting cancer cells with the RNA molecule; and a pharmaceutical composition for treating cancer includes the RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector include the double-stranded RNA molecule.

Method and pharmaceutical composition for treating cancer

The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

Use of glycan as biomarkers for autoimmune diseases

A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use

One embodiment provides a compound of Formula I that activates autophagy, a pharmaceutical composition and use thereof: 

Compounds that activate autophagy

The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from

Method of isolating anti-viral ingredients from, compositions comprising them and their medical use

A method of preparing a crystalline copper-based coordination polymer comprises preparing a mixture of copper ions and a first quaternized carboxylate pyridyl ligand; adding a second polypyridyl ligand; and forming crystals of a copper-based coordination polymer therefrom. The crystalline copper-based coordination polymer is suitable for providing a sensing platform for detecting the presence of one or more target nucleic acid sequences such as viral RNA, in particular Dengue virus and/or Zika virus RNA with high selectivity and high specificity. A method of detecting at least a first target nucleic acid sequence, in particular from a viral RNA, in particular it is Flavivirus RNA, in a sample is also provided. Further provided is a kit including the crystalline copper-based coordination polymer and an oligonucleotide probe.

Crystalline copper-based coordination polymers and their use

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, fromis used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

[object Object]

The present invention relates in a first aspect to a method of preparing a crystalline lanthanum-carboxylate coordination polymer and the crystalline lanthanum-carboxylate coordination polymer obtained or obtainable by the method. In another aspect of the present invention, also provides a method of detecting a target nucleic acid sequence in a sample.

Crystalline lanthanum-carboxylate coordination polymers and their use

One example embodiment is a lignanamide that includes a benzo-angular triquinane skeleton. The lignanamide is represented by formula (I) and any derivative of the formula (I), in which R is represented by &#x2014;OH or &#x2014;OCH3. Another example embodiment relates to a method of treating neurodegenerative disease by administering the lignanamide of the formula (I) to a person in need thereof. 

Lignanamides and a method of treating neurodegenerative diseases by using the same

A method of identifying and preferably quantifying at least one sphingolipid, in particular the sphingolipid portion in wild-typeorderivates includes preparing a test sample solution from asample, subjecting the test sample solution to liquid chromatrography with a mobile phase including at least a first and second eluting solvent; and performing a mass spectrometry after the step of subjecting. The quality and safety ofproducts can be determined and wild-typeandderivates may be differentiated via the ratio and/or presence of certain sphingolipids especially suitable as markers.

Methods of identifying and quantifying sphingolipids

A method of preparing a crystalline zwitterionic zinc(II)-carboxylate compound includes the steps of preparing a mixture of zinc(II) ions and a first pyridyl ligand having three carboxylic acid moieties; subjecting the mixture to conditions under which a precipitate is formed; separating the precipitate; adding a solvent and optionally a second pyridyl ligand to the separated precipitate; subjecting the obtained mixture to conditions under which crystals of the zwitterionic zinc(II)-carboxylate compound are formed; and separating the crystals of the zwitterionic zinc(II)-carboxylate compound. Preferably but not exclusively, the crystalline zwitterionic zinc(II)-carboxylate compound essentially consists of at least one 1D coordination polymer. The compounds are suitable for providing a sensing platform for detecting the presence or amount of target nucleic acid, particularly HIV-1 ds-DNA, with specificity, and, thus, a method of detecting a target nucleic acid sequence in a sample and a kit including the compounds and an oligonucleotide probe are also provided.

Zwitterionic zinc(II) carboxylate compounds and their use

Growing community of inventors

Taipa, Macao

Zhi-Hong Jiang